HCC – Hepatocellular Carcinoma research hub
4 indexed studies · 2 currently recruiting
- authorisedPhase I and Phase II (Integrated)- Other
Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy
This study is testing a specialised scan called a dynamic PET-CT in people with liver cancer. Researchers want to see if this detailed scan can predict whether a radiation treatment called SIRT will successfully shrink the tumour six months later, helping doctors plan better treatments in the future.
France - active not recruitingPHASE2
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure
This study is testing a new way to treat liver cancer (HCC) using two medications, Durvalumab and Tremelimumab, before and after a procedure to remove the cancer. We want to see if this combination is safe and effective for people with early-stage HCC.
France - enrolling by invitationNA
OE MRI to Predict Treatment Response After TACE in HCC Patients
This study looks at a special MRI scan before and after treatment for a type of liver cancer called HCC. We want to see if this MRI can predict how well the treatment works by checking how much oxygen gets into the tumour.
Canada - recruitingPHASE2
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
This study looks at combining a treatment called faecal microbiota transplant (FMT) with standard immunotherapy (Atezolizumab/Bevacizumab) for advanced liver cancer. We want to see if FMT can help the immunotherapy work better and if it's safe.
Germany